

# Josh Rising, M.D., M.P.H.

203-535-9983

[joshrising@gmail.com](mailto:joshrising@gmail.com)

---

Physician researcher and advocate with extensive leadership experience in the non-profit sector. Significant emphasis on project management and developing and executing long-term change strategies.

## Employment

- **Senior Clinical Advisor, Office of the Commissioner, Food and Drug Administration – September 2023 – January 2025**  
Working directly for the Commissioner, I identified and led opportunities for FDA to improve mental and behavioral health outcomes. My collaboration with DEA and other HHS agencies around prescription stimulants resulted in an event attended by over 70 senior officials, new analyses (in print) on the frequency of misuse of the medications, and changes in the federal approach to the products.
- **Principal, Rising Health Strategies – July 2020 - September 2023 and January 2025-present**  
I founded and led a boutique health policy consulting firm that resulted in federal and state public health improvements. As one project for Bloomberg Philanthropies, I produced a 120+ page detailed analysis and summary of the literature on the contribution of e-cigarettes to youth initiation and adult cessation of smoking. As part of my work with the Johns Hopkins School of Public Health, I developed principles for states and localities to use when spending money from the opioid litigation; these principles have been endorsed by over 60 state and national organizations and incorporated by several states into their planning.
- **Director, Health Care Programs, The Pew Charitable Trusts – January 2014 - June 2020**  
I oversaw multiple Pew projects, including the supervision of twenty staff, management of project budgets of over \$5 million, and ensuring that all lines of work met their board-approved deliverables. My projects—the Substance Use Prevention and Treatment Initiative, the Health Information Technology Project, the Improving End-of-Life Initiative and the Medical Device Initiative—successfully advocated for the implementation of evidence-based public health approaches at the federal and state levels through active collaboration across Pew’s departments. I brought in two external grants that allowed a 50% expansion of the substance use project and developed a new project on health information technology and stewarded it through board approval and renewal.
- **Director, Medical Devices, The Pew Charitable Trusts – January 2012 - January 2014**  
I ran Pew’s work to improve medical device safety and innovation, including the development and implementation of a strategic plan that included passage of project priorities by Congress and incorporation of our priorities by the FDA. I supervised three staff with a budget of over \$1 million.
- **Medical Officer, Office of Policy, Center for Tobacco Products, Food and Drug Administration – 2010 - 2012**  
As one of the first members of the Office of Policy, I helped establish initial priorities and procedures for the Center for Tobacco Products (CTP).
- **Health Policy Analyst, Connecticut Senate Democrats – 2008 - 2010**  
I conducted analyses and provided recommendations for the Connecticut Senate president pro tempore on key health and human services issues facing the state.
- **Robert Wood Johnson Clinical Scholars Program (RWJCSP), Yale University – 2007 - 2008**  
My areas of research included resilience in children at-risk for chronic disease and interactions between

physicians and industry. The coursework in the RWJCSP included biostatistics, clinical and health services research methods, principles and processes of community-based research, and principles of health policy and management.

- **Legislative Affairs Director, American Medical Student Association (AMSA) – 2000 - 2001**

#### Education, Training and Licensure

- **Active Connecticut medical license: 46018**
- **Board certification – Pediatrics – 2006.**
- **Pediatric Intern and Resident, Pediatric Leadership for the Underserved Track (PLUS), University of California at San Francisco – 2003-2006.**
- **Boston University, Boston, MA. M.D., M.P.H.**
- **Carleton College, Northfield, MN. BA in History, Cum Laude.**

#### Selected Testimony and Presentations

- Testified at the Heroin and Synthetic Drug Abuse Hearing held by the House Bipartisan Heroin Task Force on February 6, 2017.
- Plenary lunch presentation at AdvaMed's national conference. October 7, 2014.
- Testified before the Committee on Energy & Commerce, Subcommittee on Health, United States House of Representatives on July 22, 2014.

#### Appendix: Peer-Reviewed Publications

Whaley S, Sharfstein J, Rising J. Opioid Settlements: The Role for Addiction Medicine in Guiding Effective Spending. *J Addict Med.* 2023;17(6): 629-631.

Blaisdell L, Rising J, van Zyl A, Finn J, Vergales J. Testing and Nonpharmaceutical Interventions for Prevention of SARS-CoV-2 in 20 US Overnight Camps in Summer 2021. *Public Health Rep.* 2022;137(5): 1007-1012.

Banerjee S, Campbell B, Rising J, Coukell A, Sedrakyan A. Long-term active surveillance of implantable medical devices: an analysis of factors determining whether current registries are adequate to expose safety and efficacy problems. *BMJ Surgery, Interventions & Health Technologies.* 2019;1.

Grannis SJ, XuH, Vest JR, Kasthurirathne S, Bo N, Moscovitch B, Torkadeh R, Rising J. Evaluating the effect of data standardization and validation on patient matching accuracy. *J Am Med Infor Assoc.* 2019 May 1;26(5): 447-456.

Ratwani RM, Savage E, Will A, Fong A, Karavite D, Muthu N, Ribera AJ, Gibson C, Asmonga D, Moscovitch B, Grundmeier R and Rising J. Identifying Electronic Health Record Usability and Safety Challenges in Pediatric Settings. *Health Affairs.* Nov 2018;37(11).

Ratwani RM, Moscovitch B, Rising JP. Improving Pediatric Electronic Health Record Usability and Safety Through Certification: Seize the Day. *JAMA Pediatr.* 2018;172(11):1007-8.

Moscovitch B, Rising JP. Medical Device Identification in Claims Data. *JAMA.* 2017;318(10):1936-7.

- Wimmer NJ, Robbins S, Ssemaganda H, Yang E, Normand SL, Matheny ME, Herz N, Rising J, Resnic FS. Assessing the cost burden of United States FDA-mandated post-approval studies for medical devices. *J Health Care Finance*. 2016 Summer (Spec Features).
- Rising JP, Moscovitch B. Characteristics of pivotal trials and FDA review of innovative devices. *PloS One*. 2015;10(2).
- Rising J, Moscovitch B. The Food and Drug Administration's unique device identification system: better postmarket data on the safety and effectiveness of medical devices. *JAMA Inter Med*. 2014 Nov;174(11):1719-1720.
- Reynolds IS, Rising JP, Coukell AJ, Paulson KH, Redberg RF. Assessing the safety and effectiveness of devices after US Food and Drug Administration approval: FDA-mandated postapproval studies. *JAMA IM*. 2014;74(11):1773-9.
- Rising JP, Reynolds IS, Sedrakyan M. Delays and Difficulties in Assessing Metal-on-Metal Hip Implants. *NEJM*. June 20 2012.
- Rising J, Wasson-Blader K. Menthol and the initiation of cigarette smoking. *Tob Induc Dis*. 2011;9(Suppl 1:S4).
- Rising J, Alexander L. Marketing of menthol cigarettes and consumer perceptions. *Tob Induc Dis*. 2011;9(Suppl 1:S2)
- Newacheck PW, Kim SE, Blumberg SJ, Rising JP. Who is at risk for special health care needs: findings from the National Survey of Children's Health. *Pediatrics*. 2008;122(2):347-359.
- Rising JP, Colon-Hopkins C, Neumann A, Kaiser E, Lange D, Thaw R, Katz MH, Fuentes-Afflick E. Healthy Young Adults: description and use of an innovative health insurance program. *J Adolesc Health*. 2007;41(4):350-6.
- Schaefer BM, Rising J, Grande D, Silver-Isenstadt J, National Physicians Alliance Task Force of Prescription Privacy. Why States should ban the sale of physician prescribing data. *J Ambul Care Manage*. 2007;30(3):206-8.
- Thyne S, Rising JP, Legion V, Love MB. The Yes We Can Urban Asthma Partnership: A Medical/Social Model for Childhood Asthma Management. *Journal of Asthma*. 2006; 43(9): 667-73.
- Newacheck PW, Rising JP, Kim SE. Children at Risk for Special Health Care Needs. *Pediatrics*. 2006; 118: 334-42.
- Agrawal J, Rising JP. Resident Education and Patient Safety. *American Family Physician*. 2002 October 15: 1569-75.
- Srinivas SK, Rising JP. The ACGME is Unable to Address Residents' Overwork. *Academic Medicine*. 2001; 76(5): 397.
- McClintock TS, Rising JP, Lerner MR. Melanophore pigment dispersion responses to agonists show two patterns of sensitivity to inhibitors of cAMP-dependent protein kinase and protein kinase C. *Journal of Cellular Physiology*. 1996; 167:1-7.

#### Selected Other Publications

STAT First Opinion. How the FDA and CMS worked together on a new approach to paying for digital mental

health treatments. Meena Seshamani, Emily Parris, Doug Jacobs, Michelle Tarver, David McMullen, Josh Rising. Jan 17 2025.

How the Drug Enforcement Administration Can Improve Access to Methadone in Correctional Settings and Save Lives. Josh Rising, Sara Whaley, Brendan Saloner. May 31, 2022. White paper.

Health Affairs Blog—Creating an Agenda For Children’s Resiliency and Health. Kara Odom Walker, Josh Rising, Daniella Gratale. April 21, 2021.

Health Affairs Blog—Methadone Barriers Persist, Despite Decades of Evidence. Alaina McBournie, Alexandra Duncan, Elizabeth Connolly, Josh Rising. September 23, 2019.

Health Affairs Blog—Building Additional Serious Illness Measures Into Medicare Programs. Janet Corrigan, Josh Rising, Tom Valuck. May 25, 2017.

Health Affairs Blog—Time to Fix the Black Hole in Medicare Data. Ben Moscovitch, Josh Rising, Gregory Daniel, Joseph Drozda. June 29, 2016

Other Activities

- **National Quality Forum, Patient Safety Standing Committee – 2014– 2016**